Table SV. Researchers' ranking of unmet needs in pemphigoid diseases per continent

	Unmet need recognized?			
	Yes n (%)	No n (%)	Missing n (%)	Ranking score*
Europe (n = 18)				
 Need for more head-to-head randomized controlled trials comparing the effectiveness and safety of current treatments 	15 (83)	1 (6)	2 (11)	33
2. Need for understanding of the pathophysiology of pemphigoid for drug development	17 (94)	0 (0)	1 (6)	26
3. Need for understanding trigger mechanism (e.g. infections, drugs) in addition to genetic predisposition	17 (94)	0 (0)	1 (6)	20
4. Need for studies on personalized treatment based on patients characteristics	15 (83)	1 (6)	2 (11)	16
5. Need for humanized animal models that simulate the human eosinophilic pathogenesis and the interactions between human IgG/IgA/IgE with human Fc receptors	11 (73)	3 (17)	4 (22)	10
6. Need for animal models for studying the break of tolerance to desmosomal and hemidesmosomal constituents	12 (67)	3 (17)	3 (17)	5
7. Need for consensus on BPDAI cut-off values for staging disease severity	13 (72)	3 (17)	2 (11)	4
Asia (n = 4)				
 Need for more head-to-head randomized controlled trials comparing the effectiveness and safety of current treatments 	4 (100)	0 (0)	0 (0)	11
2. Need for studies on personalized treatment based on patients characteristics	4 (100)	0 (0)	0 (0)	6
2. Need for animal models for studying the break of tolerance to desmosomal and hemidesmosomal constituents	4 (100)	0 (0)	0 (0)	6
3. Need for consensus on BPDAI cut-off values for staging disease severity	4 (100)	0 (0)	0 (0)	4
4. Need for understanding trigger mechanism (e.g. infections, drugs) in addition to genetic predisposition	4 (100)	0 (0)	0 (0)	3
4. Need for understanding of the pathophysiology of pemphigoid for drug development	4 (100)	0 (0)	0 (0)	3
4. Need for humanized animal models that simulate the human eosinophilic pathogenesis and the interactions between human IgG/IgA/IgE with human Fc receptors	3 (75)	0 (0)	1 (25)	3
North America $(n=6)$				
1. Need for understanding of the pathophysiology of pemphigoid for drug development	6 (100)	0 (0)	0 (0)	9
2. Need for animal models for studying the break of tolerance to desmosomal and hemidesmosomal constituents	5 (83)	1 (17)	0 (0)	8
3. Need for humanized animal models that simulate the human eosinophilic pathogenesis and the interactions between human IgG/IgA/IgE with human Fc receptors	6 (100)	0 (0)	0 (0)	7
3. Need for understanding trigger mechanism (e.g. infections, drugs) in addition to genetic predisposition	6 (100)	0 (0)	0 (0)	7
Need for more head-to-head randomized controlled trials comparing the effectiveness and safety of current treatments	6 (100)	0 (0)	0 (0)	7
4. Need for studies on personalized treatment based on patients characteristics	5 (83)	1 (17)	0 (0)	1
5. Need for consensus on BPDAI cut-off values for staging disease severity	5 (83)	1 (17)	0 (0)	0

^{*}Ranking score was calculated by awarding 3 points for every time an unmet needs was ranked highest, 2 points if ranked 2nd highest and 1 point if ranked 3rd highest. BPDAI: Bullous Pemphigoid Disease Activity Index.